Abstract
Sixty patients were randomized to treatment with either emepronium bromide (Cetiprin®) 25 mg t.i.d. or placebo, both medications administered intramuscularly, after transurethral resection of the prostate. Postoperatively, the number of episodes with vesical tenesms and the need for adjuvant analgesic medication were registered. No significant differences in the number of episodes with vesical tenesms or the need for adjuvant analgesic medication were found between the patients treated with emepronium bromide and those treated with placebo.
Similar content being viewed by others
References
Bonnesen, T., Tikjøb, G., Kamper, A. L., Nielsen, A. M. B., Andersen, J. T., Jørgensen, S. J.: Effect of emepronium bromide (Cetiprin®) on symptoms and urinary bladder function after transurethral resection of the prostate.Urol. Int., 39, 318 (1984).
Jönsson, G., Zederfeldt, B.: A study of Cetiprin as a urologic drug.Urol. Int., 4, 293 (1957).
Sundwall, J., Vessman, J., Strundber, B.: Fate of emepronium bromide in man in relation to its pharmacological effects.Eur. J. Clin. Pharmacol., 6, 191 (1973).
Syversen, J. H. N., Møllestad, E., Semb, L. S.: Emepronium bromide (Cetiprin®) as spasmolytic agent in transvesical prostatectomy.Scand. J. Urol. Nephrol., 10, 201 (1976).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Jørgensen, L., Willumsen, H., Lautorp, J.R.L. et al. The effect of parenteral emepronium bromide (Cetiprin®) on postoperative vesical tenesms after transurethral resection of the prostate. International Urology and Nephrology 19, 87–90 (1987). https://doi.org/10.1007/BF02549683
Received:
Issue Date:
DOI: https://doi.org/10.1007/BF02549683